Wall Street Forgot These 3 Dividend Stocks — Now They Pay Over 5%
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Income investors tend to crowd into whatever is popular, leaving solid payers ignored. The three stocks below are in health care, telecom, and financials. Each pays at least 5%, and each has price or valuation data showing the market has lost interest. Take Pfizer (NYSE: PFE), whose share price is still 26.37% below where it was five years ago. Here’s how safe each payout looks, starting with coverage and cash flow.
Pfizer: Big Pharma Income at a Discount
Pfizer yields 5.94%, based on an annualized dividend of $1.72 per share. That falls just short of ultra-high-yield territory, but it is a strong high-yield payout for a large drugmaker. The stock trades at $28.56, down 2.04% over the past month and below its 52-week high of $30.99. It also trades at about 10 times forward earnings, a low multiple for a company with growing oncology and cardiology franchises.
Dividend Safety Read
Earnings cover the dividend comfortably. Full-year adjusted EPS guidance was raised to $2.95-$3.05[1], well above the $1.72 annual payout. Cash coverage is tighter. Pfizer’s free cash flow yield of 5.51% sits slightly below its dividend yield, so the dividend uses nearly all of the free cash flow.
Interest coverage of 6.52 times and net debt to EBITDA of 2.76 points to a manageable balance sheet. Management has prioritized the dividend over buybacks, with no share repurchases in 2026[1] while the company pays down debt. Pfizer paid $4.9 billion[2] in common dividends in the first half alone.
Looking at the track record, the quarterly payout rose every year from $0.38 in 2020 to $0.43 in 2025 and has held there through 2026. Retirees should remember that Pfizer cut its quarterly dividend from $0.32 in 2008 to $0.16 in 2009. A 2026 freeze is a yellow flag worth tracking, and it is the kind of early signal we cataloged in a free report on the seven warning signs a big yield is about to be cut.
Bull Case for Income Investors
The core business is growing. Third-quarter adjusted EPS of $0.87[1] beat the $0.73 consensus. The non-COVID portfolio grew 7%[1] operationally, and launched or acquired products rose 32%. Padcev jumped 55%[1], and the Vyndaqel family reached $1.773 billion. Berobenatide, Pfizer’s obesity candidate, produced positive Phase 2b data and is moving into 10 Phase 3 studies[2]. Chief executive Albert Bourla said Pfizer “had another strong quarter with commercial momentum and disciplined execution.”[1]
Key Risk
Patent expirations are the main threat. Pfizer expects about a $1.1 billion[1] revenue loss from generic and biosimilar competition this year. Eliquis, which brought in $2.523 billion[1] last quarter, faces generic entry ahead. Paxlovid revenue has already fallen 63%[1].
Verizon: An Ultra-High-Yield Telecom Trading Below Its Highs
Verizon (NYSE: VZ | VZ Price Prediction) yields 6.04%, making it an ultra-high-yield stock with an annualized dividend of $2.83 per share. At $46.33, it trades below its 52-week high of $50.88 and below its 200-day moving average of $47.15. The five-year gain is just 23.59%, and the stock sells for about 9 times forward earnings. Wall Street remains lukewarm, with 12 analysts rating it a hold.
Dividend Safety Read
Cash flow is the strongest part of the Verizon story. Third-quarter free cash flow reached $7.801 billion[3], up 13.88% from a year earlier, on operating cash flow of $11.517 billion. Adjusted EPS of $1.31[3] easily covered the $0.7075 quarterly dividend. Full-year adjusted EPS guidance of $5.04 to $5.06[3] sits well above the annual payout. Net unsecured debt was 2.5[4] times adjusted EBITDA as of the second quarter.
Its track record is long. The quarterly dividend has climbed from $0.43 in 2008 to $0.7075 today, and the July payment was higher in every year of that span. The latest increase, from $0.69, took effect with the April payment.
Bull Case for Income Investors
Verizon is adding subscribers again. Postpaid phone net additions came in at 406,000[3], compared with 44,000 a year earlier. Adjusted EBITDA margin expanded from 37.8% to 40.2%[3]. Management now expects free cash flow growth near 12%[3] this year. Verizon has also bought back $4.0 billion[3] of stock under a program of up to $4.5 billion. Chief executive Dan Schulman said Verizon “delivered another record-breaking quarter.”[3] With a beta of 0.26, the stock has also moved far less than the broader market, which means less price volatility for income-focused investors.
Key Risk
Debt is the pressure point. Verizon has $166.2 billion[3] in outstanding debt, and interest expense rose 17.2% year over year. Higher borrowing costs take cash that could otherwise go to dividend growth.
OneMain Holdings: The Highest Yield Here, With Credit Risk Attached
OneMain Holdings (NYSE: OMF) fits the financials slot because Franklin Templeton (NYSE: BEN) no longer makes. The asset manager rallied 66.82% over the past year, which drove its yield down to 3.68%. OneMain yields 7.72% on an annualized dividend of $4.20 per share, which makes it ultra-high-yield. The consumer lender is down 12.74% year to date and trades at $54.64, well below its 52-week high of $66.89. At about 8 times trailing earnings and 7 times forward earnings, the market is pricing it like a lender headed for trouble.
Dividend Safety Read
Earnings still cover the payout. Third-quarter adjusted EPS of $1.51 topped the $1.05 quarterly dividend, and trailing EPS of $6.57 sits well above the annual payout. Capital generation, the company’s own measure of distributable earnings, rose to $284 million from $272 million. Cash on hand climbed to $936 million. The regular quarterly dividend rose from $0.95 in 2022 to $1.00 in 2023, then to $1.04 in 2024, and has been $1.05 since late 2025. OneMain also paid several special dividends between 2019 and 2021.
Bull Case for Income Investors
The loan book is growing while credit improves. Managed receivables reached $28.1 billion, up 9%, and originations rose 17% to $4.5 billion. The net charge-off ratio fell to 6.89% from 7.77% in the prior quarter. Credit card receivables grew to $1,383 million from $834 million. Chief executive Doug Shulman noted the company is “confident in our ability to deliver attractive returns for shareholders well into the future.”
Key Risk
OneMain has the most yield-trap risk of the three. It lends to nonprime borrowers so that a weaker job market would hit its results quickly. The provision for loan losses rose to $615 million from $488 million, and adjusted EPS fell short of the $1.56 consensus. Watch charge-offs every quarter.
Three Overlooked Yields, Three Different Safety Profiles
Verizon offers the most reliable coverage, backed by rising free cash flow and a dividend that has climbed every year since 2008. Pfizer pairs a high-yield payout with a growing non-COVID business, but free cash flow coverage is thin, and that needs watching. OneMain pays the most and has the most credit risk, so its income depends more heavily on the economy holding up. Weak share prices created all three yields, and each company’s earnings still cover its dividend.
Contact [email protected] for any questions or corrections.







